Nanobiotix (NASDAQ:NBTX – Get Free Report) will likely be releasing its earnings data before the market opens on Monday, March 24th. Analysts expect Nanobiotix to post earnings of ($0.58) per share and revenue of $3.55 million for the quarter.
Nanobiotix Stock Performance
Shares of NBTX stock opened at $3.62 on Friday. The firm has a 50 day moving average price of $3.51 and a two-hundred day moving average price of $3.90. Nanobiotix has a 12-month low of $2.76 and a 12-month high of $7.51.
Wall Street Analyst Weigh In
Separately, UBS Group upgraded shares of Nanobiotix to a “hold” rating in a research report on Monday, February 17th.
About Nanobiotix
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Read More
- Five stocks we like better than Nanobiotix
- How to Use the MarketBeat Stock Screener
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
- What is the Nikkei 225 index?
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- EV Stocks and How to Profit from Them
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
